A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Clinical trial NCT05560399 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05560399
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-02-06
- Primary completion
- 2026-11-01
- Enrollment
- 7
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.